Conference Information

Welcome Message

Dear Colleagues and Friends,

The event Diabetes 2021 was very successful, and I would like to thank everyone who are participated in making this event successful and for your support.

I wholeheartedly welcome you back to share your knowledge, experience and creative idea in this conference through interacting with worldwide experts from the field of endocrinology, and metabolism.

It is a great honour to have the opportunity to invite Diabetes Experts and Researchers, Academicians, Scientists, Industry Professionals and students and other affiliated individuals to the 7^th International Conference on Endocrinology, Diabetes and Metabolism to be held virtually on June 8-9, 2022.

The conference includes keynote presentations, workshops, technical oral presentation, and poster presentations. By sharing research, participating in forums and collaborating with one another, your work will continue to impact the Diabetes field.

On behalf of the Organizing Committee of Diabetes 2022, we would like to express our warmest welcome to all of you who are participating in Diabetes 2022.

We look forward to see your participation.

Regards
Diabetes 2022
Organizing Committee

About the Conference

Diabetes 2022- is a prodigious accomplishment in the field of Diabetes endocrinology and metabolism assisted the attendees in gaining proper insights, as stated. The gathering, held in Germany was organized by the most distinguished personalities of the field and was nurtured to be a massive successful one by the presence of many notable speakers.

Now, after the extra ordinary response for Diabetes Congress 2021, We are ready to make Diabetes 2022 a grand victory!

After gaining a very favourable outcome out of the past conference in the Diabetes Conference series, CPD accredited- International conference on Endocrinology, Diabetes and Metabolism– Diabetes 2022, Pulsus takes all the pride in announcing the Upcoming Conference in the successful series of Diabetes Conferences.

7^th International Conference on Endocrinology, Diabetes and Metabolism- Diabetes 2022

Diabetes 2022- The one-day gathering of world-renowned researchers, endocrinologists, experts and practitioners in the field of Diabetes is scheduled on June 8-9, 2022.

The International Conference on Endocrinology, Diabetes and Metabolism- 2022 is going to happen on the 8^th of June 2022. Diabetes 2022 desires at integrating all the renowned Researchers and Doctors, Medical professionals, Fellowship holders, Residents, Pharmaceutical industries and Healthcare industries in the field of Endocrinology and Diabetes. The objective of this conference is to gather like-minded coteries to facilitate the flow of ideas, thoughts, suggestions and motivations

This Diabetes Conference runs on the theme’ Evincing the therapeutic approaches and development in Diabetes’ , which concedes that Diabetes 2022 will act as a platform for exploring the novelties in the field of Endocrinology. In this gathering the major breakthroughs related to the field of endocrinology and diabetes are about to be deliberated and cognizance on the treatments are to be shared.

Diabetes 2022 will serve a great opportunity for the delegates of universities and Institutions as it allows people to interrelate with world-class Endocrinologists, Diabetologists and Businesspersons. Diabetes 2022 will not simply be a stage estimation in a gigantic event of people, yet additionally it’s an attempt to spread research advances in the ever evolving-field research of Endocrinology and Diabetes.

The scientific event focuses of this Diabetic Summit on the research which is currently being undertaken in the field of Endocrinology and metabolism including all the related fields.

Diabetes 2022 Conference embraces Keynote speeches, Oral, Poster and Video Presentations. The fostered participants can confirm their participation by registering in Diabetes 2022. All the accepted abstracts will be published in the supporting journals like Journal of Diabetes and Metabolism.

This conference will help the attendees in building a strong professional network by facilitating a fresh perspective of ideas, knowledge in recent advancements, one-on-one engagements and streamlining of techniques. Diabetes 2022 Conference is organized under the belief that one-on-one interactions and discussions open door to new innovations and inventions. We are proud facilitators of such an opportunity.

We soulfully welcome you to Diabetes 2022 will inspire you and will result in new collaborations and friendships!

Sessions and Tracks

Track 1 : Diabetes: Types and Complications

Diabetes is a major public health problem that is moving toward epidemic proportions comprehensively. Around the world, the predominance of chronic, non-communicable diseases is expanding at an alarming rate. Confusions from Diabetes, for example, coronary corridor and fringe vascular malady, stroke, diabetic neuropathy, removals, renal disappointment, and visual deficiency are bringing about expanding inability, diminished future and tremendous wellbeing costs for essentially every general public. Diabetes is sure to be a standout amongst the most difficult medical issues in the 21st century. In this session, we are focusing on the complexity of Diabetes.

Track 1-1Type 1 Diabetes
Track 1-2Type 2 Diabetes
Track 1-3Prediabetes
Track 1-4Gestational Diabetes
Track 1-5Nerve Disease
Track 1-6Kidney disease
Track 1-7Oral Complications
Track 1-8Steroid diabetes
Track 1-9High Blood Pressure

Related Conferences: 3^rd Global Experts Meeting on Diabetes, Hypertension & Metabolic Syndrome | 19^th Global Conference on Diabetes and Nursing Care | 14^th International Conference Diabetes & Metabolism | 4^th International Conference on Diabetes and Healthcare | 5^th Global Conference on Diabetes and Endocrinology | 29^th European Diabetes Congress | 32^nd International conference on Paediatrics and Adolescent Diabetes | 4^th International Conference on Endocrinology and Metabolism

Track 2 : Genetics of Diabetics

Diabetes mellitus is a heterogeneous group of disorders described by persistent hyperglycemia. Type 1 and type 2 both are caused by a combination of genetic and environmental risk factors. In any case, there are other rare forms of diabetes that are directly inherited. These include maturity-onset diabetes and diabetes because of mutations in mitochondrial DNA. Within the following decade, the qualities that the genes that increase the risk of developing all forms of diabetes will likely be known. It is, in this way, important that researchers, wellbeing experts, health professionals, and members of the population at large consider how to maximize the advantages, and minimize the disadvantages of predictive genetic testing for diabetes.

Track 2-1Genetics of metabolic syndrome
Track 2-2Role of genetics in type 2 diabetes
Track 2-3Genes responsible for type 2 diabetes
Track 2-4Mechanism and Variants of diabetes gene
Track 2-5X-linked neonatal diabetes mellitus
Track 2-6Genetic Mutation

Track 3 : Nutrition & Diet

Nutrition and physical activity are essential parts of a healthy lifestyle when we have diabetes. Some foods raise blood glucose more than others. To deal with our blood glucose, we need to balance what we eat and drink with physical activity and diabetes medicine if we take any. In recent years, there has been much new proof evidence demonstrating the potentially preventable nature of type 2 diabetes, especially by the implementation of lifestyle measures such as weight control and exercise. In perspective on this and the devastating health impact of the disease, it seems prudent that primary prevention should be a major priority. This session, concentrating on nutritional intervention in the prevention of type 2 diabetes is used to make disease-specific recommendations.

Track 3-1Medical nutrition therapy
Track 3-2Balanced diet index
Track 3-3Low glycaemic index diet
Track 3-4Ketogenic Diet for Diabetes
Track 3-5Meal replacement diet plans
Track 3-6Poultry Nutrition

Track 4 : Insulin Medications

The objectives of this session are to reduce morbidity and to prevent complications. Medications that reduce insulin resistance include metformin, thiazolidinedione and biguanides, which have antihyperglycemic effects and insulin-sensitizing. Vast amounts of insulin are additionally utilized in overcoming insulin resistance. Reaction to the normal dose of insulin is seen in occurrences in which the resistance is due to enhanced destruction at the subcutaneous injection site. Antiobesity drugs, for example, orlistat, may reduce insulin resistance and related cardiovascular risk factors through weight reduction and other mechanisms.

Track 4-1Insulin Medication of Type 1 Diabetes Mellitus
Track 4-2Insulin Medication of Type 2 Diabetes Mellitus
Track 4-3Insulin Therapy
Track 4-4Insulin with Oral Medications
Track 4-5Types of insulin treat diabetes
Track 4-6Postprandial Hyperglycemia

Track 5 : Diabetes and Skin complications

Diabetes can affect all aspects of the body, including the skin. Actually, such issues are sometimes the first sign that a person has diabetes. A variety of dermatologic indications have been connected with diabetes mellitus; these conditions fluctuate in seriousness and can be benign, deforming, and even life-threatening. Such skin changes can insight into patients’ glycemic control and might be the first sign of metabolic derangement in undiagnosed patients with diabetes. Recognition and management of these conditions are imperative in maximizing the quality of life and in avoiding serious adverse effects in patients with diabetes.

Track 5-1Necrobiosis Lipoidica
Track 5-2Acanthosis Nigricans
Track 5-3Acrochordons
Track 5-4Granuloma Annulare
Track 5-5Eruptive Xanthoma
Track 5-6Diabetic Dermopathy (shin spots)

Track 6 : Obesity complication and Management

Obesity is the main source of preventable disease and passing in the world. In recent years, the number of overweight people in industrialized countries has expanded, altogether, to such an extent that the World Health Organization (WHO) has considered obesity an epidemic. In the United States, 69% of the grown-up populace is overweight or obese. In Canada, the self-reported data demonstrate that 20% of men and 17% of women are obese and 40% of men and 27% of women are overweight. People who are obese are at a lot higher hazard for serious medical conditions, for example, heart attack, high blood pressure, stroke, diabetes, gallbladder disease, and different cancers than people who have a healthy weight.

Track 6-1Lipid and Glucose Metabolism
Track 6-2Obesity in pregnancy
Track 6-3Etiology of obesity
Track 6-4Proteins and micronutrients
Track 6-5Surgical management of obesity
Track 6-6Weight Management

Track 7 : Diabetes Podiatry

Due to the peripheral nerve dysfunction related to diabetes (diabetic neuropathy), patients have a reduced ability to feel torment. This implies minor wounds may remain undiscovered for quite a while. People with diabetes are likewise in danger of developing a diabetic foot ulcer. The research assesses that the lifetime occurrence of foot ulcers inside the diabetic community is around 15% and may move toward becoming as high as 25%. Those few patients are then 50% more likely to undergo another lower limb amputation. As such, diabetic foot care is one of the most essential parts of diabetes management and so we included this session at this wonderful gathering to discuss.

Track 7-1Diabetic foot Ulcer
Track 7-2Diabetic foot pathophysiology
Track 7-3Diabetic Charcot Neuropathy
Track 7-4Diabetic Foot and Ankle

Track 8 : Diabetes and Cardiovascular Diseases

Diabetes mellitus aggravates mechanisms underlying atherosclerosis and heart failure. Unfortunately, these mechanisms are not sufficiently modulated by therapeutic strategies focusing solely on optimal glycemic control with currently accessible drugs or approaches. Women with diabetes have a considerably more serious danger of coronary illness compared to those of similar age who don't have diabetes. Actually, cardiovascular disease is by a long shot the most frequent reason for death in the two people with diabetes. Lamentably, in patients with diabetes, improvement in survival after a heart attack has been not exactly half as much as in the overall population. The main objective of this conference is to build open attention to early discovery and better treatment of diabetes to prevent its complications.

Track 8-1Heart disease
Track 8-2Stroke
Track 8-3Diagnosis methods of Heart Disease
Track 8-4Atherosclerosis
Track 8-5Hypertension

Track 9 : Diabetes and Cancer

People with diabetes are at higher risk for some, but not all, forms of cancer. The relationship between the two diseases is complex and surrounded by unanswered questions. Diabetes is associated with increased risk for some cancers (liver, pancreas, endometrium, colon and rectum, breast, bladder). Diabetes is associated with a reduced risk of prostate cancer. For some other cancer sites, there appears to be no association or the evidence is inconclusive. We hope this session to address some important questions about the meaningful association between diabetes and cancer incidence or prognosis.

Track 9-1Colon cancers
Track 9-2Kidney cancers
Track 9-3Endometrial cancers
Track 9-4Insulin secretagogues
Track 9-5Thiazolidinediones

Track 10 : Biomarkers and Diabetes

Biomarkers have an imperative impact in leading clinical trials and treating patients. Advances in molecular diagnostics help restorative experts make proficient, scientifically valid decisions. All the more efficient discovery and utilization of biomarkers in the development of anti-diabetes drugs will rely on accelerating or understanding of the pathogenesis of diabetes and explicitly its macrovascular complications. Procedural enhancements from different fields, particularly disease, are starting to demonstrate the route towards better models of diabetes pathogenesis and molecular biomarker discovery.

Track 10-1Serum biomarkers for diabetes
Track 10-2Carbonyl stress
Track 10-3Pulse wave analysis
Track 10-4Auto fluorescence
Track 10-5Biomarkers of vascular function in diabetes
Track 10-6Salivary biomarkers for diabetes
Track 10-7Novel biomarkers for diabetes
Track 10-8Glycated haemoglobin biomarkers

Track 11 : Risk Factors and Related Diseases of Diabetes

Our chances of developing type 2 diabetes depend on a combination of risk factors such as our genes and lifestyle. Although we can’t change risk factors such as family history, age, or ethnicity, we can change lifestyle risk factors around eating, physical activity, and weight. These lifestyle changes can affect our chances of developing type 2 diabetes.

Track 11-1Diabetic Retinopathy
Track 11-2Prediabetes
Track 11-3Unexplained weight loss
Track 11-4Slow-healing sores
Track 11-5Mastopathy
Track 11-6Diabetes insipidus
Track 11-7Coeliac disease

Track 12 : Treatments for Diabetes

Treatments for diabetes depend on your type of diabetes, how well controlled your blood glucose level is and your other existing health conditions. Successful pancreas and islet transplantation can normalize glucose levels and mitigate microvascular complications of type 1 diabetes . If lifestyle changes aren’t enough to lower your blood sugar, you’ll need to take medication. Insulin is the main treatment for type 1 diabetes. It replaces the hormone your body can’t be able to produce

Track 12-1Stem-cell based therapy
Track 12-2Immunotherapy
Track 12-3Pancreas/islet transplantation
Track 12-4Exogenous insulin injection
Track 12-5Gene therapy

Track 13 : Stem Cell Therapy for Diabetes

Stem cell therapy holds immense guarantee for the treatment of patients with diabetes mellitus. Research on the capacity of human embryonic stem cells to separate into islet cells has characterized the developmental stages and translation factors associated with this procedure. As a result, alternative forms of stem cell therapies, for example, umbilical cord stem cells, induced pluripotent stem cells and bone marrow-derived mesenchymal stem cells, have turned into an area of serious study. Recent advances in stem cell therapy may transform this into a realistic treatment for diabetes in the near future.

Track 13-1Islet cell transplantation
Track 13-2Mesenchymal stem cell therapy
Track 13-3Umbilical Stem Cells
Track 13-4Embryonic Stem Cell Research
Track 13-5Type 1 Diabetes Beta Cells
Track 13-6Hyperthyroidism

Track 14 : Thyroid glands Disorders

The thyroid organ is prone to several very distinct problems, some of which are very common These issues can be separated into [1] the formation of nodules or lumps within the thyroid which are worrisome for the presence of thyroid cancer, [2] those concerning the production of hormone (too much, or too little) [3] those due to increased growth of the thyroid, causing compression of important neck structures or simply appearing as a mass in the neck, [4] those which are cancerous. Since the principle motivation behind thyroid hormone is to "run the body's metabolism," it is justifiable that individuals with this condition will have indications related to slow metabolism.

Track 14-1Thyroid and thymus
Track 14-2Role of the thyroid gland
Track 14-3Hypothyroidism

Track 15 : Herbal Therapy for Diabetes

There are heaps of chemical agents accessible to control and to treat diabetic patients, yet all-out recovery from diabetes has not been reported for up to this date. An alternative to these manufactured operators, synthetic agents, plants provides potential sources of hypoglycemic drugs are generally utilized in several traditional systems of medicine to prevent diabetes. A few medicinal plants have been researched for their medicinal use in various types of diabetes and have shown up in various scientific journals. The impacts of these plants may delay the advancement of diabetic difficulties and correct the metabolic irregularities using an abnormality using a variety of mechanisms. An impressive number of plants were exposed to clinical trials and were discovered effective. In addition, during the past few years, numerous phytoconstituents in charge of antidiabetic impacts have been separated from hypoglycaemic plants.

Track 15-1Herbs and Supplements
Track 15-2Herbal Metformin
Track 15-3Traditional Chinese medicine
Track 15-4Anti-diabetes plants

Track 16 : Nanotechnology in Diabetes

Nanotechnology in diabetes investigate has encouraged the advancement of novel glucose estimation and insulin delivery modalities which hold the possibility to drastically improve quality of life for diabetics. Current advancement in the field of diabetes explore at its interface with nanotechnology is our centre of attention. Specifically, we look at glucose sensors with nanoscale components including metal nanoparticles and carbon nanostructures. A portion of the applications of nanotechnology in treating diabetes mellitus are artificial pancreas, rather than pancreas transplantation utilization of artificial beta cells, for the oral conveyance of insulin use of nanospheres as biodegradable polymeric carriers and so on. In this session, the utilization of nanotechnology in treating diabetes mellitus will be discussing.

Track 16-1Applications of Nanotechnology for Diabetes Management
Track 16-2Nano Medicine
Track 16-3Artificial Pancreas
Track 16-4Monitoring Glucose levels
Track 16-5Nanoporous immunoprotective devices

Track 17 : Endocrinology and Metabolism

The endocrine issue is consistently astounding, including a mixed picture of hyposecretion and hypersecretion because of the information parts related to the endocrine system. For example, most kinds of hyperthyroidism are connected with an excess of thyroid hormone and a low dimension of thyroid animating hormone. Patients with multi-transfused thalassemia major may make serious endocrine complexities because of iron overload. Syndrome X is a term that is much of the time associated with the dissipates that exist together in various people with different sorts of cardiovascular disease (CVD) and furthermore diabetes in association with insulin resistance, hyperinsulinemia and cell ionic abnormality.

Track 17-1Environmental Endocrinology
Track 17-2Neuro Endocrinology
Track 17-3Metabolic disorders
Track 17-4Symptoms and Diagnosis
Track 17-5Management of Metabolic syndrome

Track 18 : General Pediatrics

Type 1 diabetes is a constant disease described by the body's inability to produce insulin because of the auto-immune system demolition of the beta cells in the pancreas. Most pediatric patients with diabetes have type 1 and a lifetime reliance on exogenous insulin. This observable underneath portrays the impacts of insulin lack. Dietary nutrient D supplementation is related to reduce the danger of type 1 diabetes. Ensuring sufficient nutrient D supplementation for infants could turn around the trend in the incidence of type 1 diabetes. The goal of this session in type 1 diabetes is to avoid the acute and chronic complications of the disease.

Track 18-1Pediatric Endocrinology
Track 18-2Pediatric Diabetes
Track 18-3Pediatric Obesity
Track 18-4Pediatric Nursing
Track 18-5Pediatric Genetics

Track 19 : Gynaecologic Endocrinology and Infertility

Diabetes type 1 and type 2 ought to be considered in the differential diagnosis of menstrual abnormalities and infertility. Reproductive period of diabetic ladies might be decreased because of delayed menarche and premature menopause. During the reproductive years, diabetes has been related to menstrual abnormalities, for example, secondary amenorrhea and oligomenorrhea. Ladies with persistent menstrual abnormalities in spite of sufficient treatment need to be approached by broader evaluation, which will incorporate the examination of the hypothalamic– pituitary– ovarian axis and the hormonal status, anti-ovarian autoantibodies, presence of autoimmune thyroid disease and hyperandrogenism.

Track 19-1In vitro fertilization
Track 19-2Fertility preservation
Track 19-3Polycystic ovarian syndrome
Track 19-4Ovarian cysts
Track 19-5Pelvic mass and adhesions

Track 20 : Neuro Endocrinology

The central neuroendocrine systems serve in as an interface between the brain and a significant number of the peripheral endocrine systems. A neuroendocrine system can be characterized as the glands and non-endocrine tissues, arrangements neurons and hormones, the neurochemicals and humoral signs they produce and receive, that work in a coordinated manner to collectively regulate a physiological or behavioural state. In this session, we define and describe different types of neuroendocrine systems, and review the basic integrative mechanisms that each people to operate under normal physiological circumstances.

Track 20-1Homeostasis
Track 20-2Growth Hormone
Track 20-3Obstructive Sleep Apnea Risk
Track 20-4Neuro inflammation
Track 20-5Pituitary

Track 21 : Advanced Technologies for the Treatment of Diabetes

Contribution from continuous glucose monitors (CGMs) is a basic component of artificial pancreas (AP) frameworks, however, CGM execution issues keep on restricting advancement in AP research. While G4 PLATINUM has been incorporated into AP frameworks around the globe and used in numerous successful AP controller possibility studies, this system was intended to address the needs of overall CGM users as an adjunctive use system. This session explicitly addresses the heightened performance requirements for future AP studies.

Track 21-1New Therapeutic Mechanisms for Diabetes
Track 21-2New Discovery and Treatment for Type 2 Diabetes
Track 21-3Exploring novel therapies in diabetes treatment
Track 21-4Integrative gaming
Track 21-5CGM

Track 22 : Business and Economics of Diabetic Products

Diabetes is a global disease. The field of diabetes innovation to advance and in order for diabetes products containing novel advancements to be developed and used, these items will need to survive economically. Financial conditions and approaches of national different administrative bodies that control access to therapeutic advances must be positive in order for a patient in that country to have access to technology, and these arrangements are frequently extraordinary in every nation. Approximately 250 million people affected by diabetes around the world, diabetes is extracting an expanding toll from the world economy. People with diabetes acquire medical costs that are a few times higher than those without diabetes. Moreover, diabetes prompts critical aberrant expenses to the economy through early retirement and a disproportionate requirement for sick days and disability. As the U.S. populace becomes more established and fatter, it may be foreseen that diabetes predominance rates and future expenses of this sickness may develop at much quicker rates than would be extrapolated from current prevalence rates.

Track 22-1Innovation in Diabetes products
Track 22-2RAGE
Track 22-3Economic of drug delivery
Track 22-4Market analysis of Diabetes products

Market Analysis

We aspire and expect the Endocrinology 2021 theme to inspire several people all around the world, research avenues, and look forward to discussing ideas, findings, and synergies, in this International Conference which is going to be held in Italy on January 14 & 15, 2022.

The demand for endocrine testing increases due to the maturing incidences of endocrine disorders such as hyperthyroidism and adrenal insufficiency. The swelling diabetic, geriatric and obese population worldwide is expected to promote market growth. Furthermore, amplifying healthcare awareness among individuals coupled with increasing government support is expected to increase the diagnosis at an early, thereby contributing to the growth of the endocrine testing market.

According to the findings of the International Diabetes Conference, someone dies from diabetes or its complications every seven seconds. The majority of the deaths occur in people under the age of 60. The prevalence of diabetes has increased more rapidly in developing countries.

Diabetes is projected to grow to 9.9% of the global population by 2045. In 2017, a population of 424.9 million people with diabetes would rise to 48 percent or about 628.6 million people. Statistically, half of all deaths from hyperglycemia occur before the age of 70.

By the end of 2021, Dubai's diabetes product market is estimated to be worth USD 1.42 billion. For the period 2016-2021, the market is expected to expand at a CAGR of nearly 6.29 percent.

In the present situation, North America is the most dominant region, with the United States responsible for more than one-third of the global market share. Europe follows North America. Europe is the world's second-largest market for diabetes products. This can be due to the region's rapidly aging population. Due to developments in the APAC and Latin American regions, this growth is expected to saturate in the future. In terms of market share, these economies are projected to surpass Europe.

7th International Conference on
Endocrinology, Diabetes and Metabolism

Quick Links

Theme: A Scientific Forum on Endocrinology, Diabetes and Metabolism.